Shasqi to Present Updated Clinical Data on SQ3370 at the 2022 ASCO Annual Meeting

No observed dose-limiting toxicity to date when SQ3370 is administered at doses up to 12 times higher than conventional doxorubicin; dose escalation is ongoing SAN FRANCISCO, CA, May 31, 2022 – Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advanced solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago, IL, on June 3-7, 2022. Presentation details: Abstract Title: Interim Phase 1 results for SQ3370 in advanced solid tumors Abstract Number: 3085 Poster Number: 77 Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT Key highlights include: 26 patients received treatment with SQ3370 and as of the data cutoff date, 21 patients were evaluable 77% of patients had metastases with a median number of 2 metastatic sites (1-5); most frequently lung (50%) and more than 50% being previously treated with doxorubicin Escalating doses of SQP33 protodrug ranging from 0.38x to 12x the molar equivalent of conventional doxorubicin per cycle along with a dose of 10 or 20 mL of SQL70 were administered SQ3370 was well tolerated with 62% of patients receiving more than 500 mg/m 2 cumulative doxorubicin equivalents given as SQP33 The most common treatment emergent adverse events reported were nausea, fatigue, anemia, and constipation At a median follow-up of 9.2 weeks, of the 21 evaluable patients, 71% had stable disease, with a median duration of 80 days Dose escalation continues as the maximum tolerable dose has not yet been reached SQ3370 demonstrates proof of concept for the CAPAC platform ‍

The release as fetched from its publisher. shasqi.com ↗